Investigation of the distribution of different major HLA-A alleles in patients with chronic hepatitis B in Southern China regions
Mingfeng LIANG,Shiwu MA,Lecheng YU,Dalin WU,Zhanghui WANG,Jinglin HUO
DOI: https://doi.org/10.3969/j.issn.1008-1704.2007.04.006
2007-01-01
Abstract:Objective To investigate the distribution of HLA-A11, A2, A24, and A33 alleles in chronic hepatitis B virus (CHB) patients in Southern China, and to provide background information for the screening of new HBV CTL epitopes. Methods Chromosomal genomic DNA specimen extracted from peripheral blood of 267 patients and 300 healthy donors were obtained for HLA-A genotyping with PCR-SSP assays, and the data were analysed with SPSS10.0 software.Results The results of that the frequency of HLA-A11, A2, A24 and A33 alleles was 57%, 41%, 21% and 7%, respectively in CHB patients in Southern China, and the most common allele is HLA-A11 which is about 16% more than that of HLA-A2. The frequency of these four alleles in healthy donors was 57%, 46%, 24% and 14% respectively, and HLA-A11 is about 11% more than that of HLA-A2. Only the distribution of HLA-A33 between the two groups had signifiacant difference. The combination of HLA-A2/A11, A2/A24, A2/A33, A11/A24, A11/A33 or A24/A33 alleles was 17%, 4%, 1%, 16%, 4%, 0.4% in CHB patients, and 18%, 8%, 4%, 11%, 5%, 1% in healthy donors respectively; there was no significant difference between the two groups. The distribution of HLA-A11, A2, A24 and A33 alleles was similar between HBeAg-positive and HBeAg-negative CHB patients.Conclusion HLA-A11, A2, A24 and A33 are the major HLA-A alleles in CHB patients of Southern China, of them the most common one is HLA-A11. The importance for identification of HLA-A11-restricted and HBV-specific new CTL epitopes is no less than that of HLA-A2-restricted HBV-specific CTL epitopes for the research of basic and clinical immunology of HBV infection. The distribution of these four major HLA-A alleles and their combination patterns have no significant differences between HBeAg-positive and HBeAg-negative CHB patients, but their influence on clinical features and the response of antiviral therapies in CHB patients should be further investigated.